Financial

CinCor Pharma Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) — CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases, today announced the pricing of its underwritten public offering, which was upsized to an aggregate […]

Aziyo Biologics Announces $25 Million Loan Facility with SWK Holdings

Provides Additional Working Capital to Further Fund Growth Initiatives SILVER SPRING, Md., Aug. 10, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO) (the “Company”), a commercial-stage regenerative medicine company announced today that it has entered into a $25 million credit facility from SWK Holdings Corporation. The new credit facility […]

Biofourmis Raises Additional Funding from Intel Capital in Series D Extension and Names Top Healthcare Leaders to its Board

Additional funding brings Series D round to $320M total Trevor Fetter, MBA, senior lecturer on the faculty of Harvard Business School and former longtime Tenet Healthcare chairman and CEO, named to Board Sachin H. Jain, physician executive with government, pharmaceutical, payer and provider experience, joins Board BOSTON, Aug. 10, 2022 /PRNewswire/ — Biofourmis, a Boston-based global leader in […]

Aziyo Biologics Co-Founder and Regenerative Medicine Pioneer, Dr. Randy Mills, appointed Chief Executive Officer

SILVER SPRING, Md., Aug. 09, 2022 (GLOBE NEWSWIRE) — Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company, today announced that Aziyo co-founder C. Randal (Randy) Mills, Ph.D. has assumed the President and Chief Executive Officer role on an on-going basis. Dr. Mills, who is internationally recognized for his […]

Ionis reports second quarter financial results and recent business achievements

Reported positive eplontersen ATTRv-PN data, on track to file NDA in H2:22 Tofersen NDA under priority review, PDUFA January 25, 2023 Completed enrollment in pelacarsen Lp(a) HORIZON and olezarsen BALANCE Phase 3 studies On track to achieve 2022 financial guidance Webcast today, August 9, 2022, at 11:30 a.m. Eastern Time CARLSBAD, Calif., Aug. 9, […]

Stereotaxis Reports 2022 Second Quarter Financial Results

ST. LOUIS, Aug. 09, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial results for the second quarter ended June 30, 2022. “Despite macro pressures and the poor optics of our financial results, Stereotaxis is making significant progress […]